Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database

Bruce C M Wang, Ping-Ning Hsu, Wesley Furnback, John Ney, Ya-Wen Yang, Chi-Hui Fang, Chao-Hsiun Tang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of the joints.

OBJECTIVES: This research aims to estimate the economic burden of RA in Taiwan.

METHODS: The National Health Insurance Research Database (NHIRD), a claims-based dataset encompassing 99 % of Taiwan's population, was applied. We used a micro-costing approach for direct healthcare costs and indirect social costs by estimating the quantities and prices of cost categories. Direct costs included surgeries, hospitalizations, medical devices and materials, laboratory tests, and drugs. The costs and quantities of the direct economic burden were calculated based on 2011 data of NHIRD. We identified RA patients and a control cohort matched 1:4 on demographic and clinical covariates to calculate the incremental cost related to RA. Indirect costs were evaluated by missed work (absenteeism) and worker productivity (presenteeism). For the indirect burden, we estimated the rate of absenteeism and presenteeism from a patient survey. Costs were presented in US dollars (US$1 = 30 TWD).

RESULTS: A total of 41,269 RA patients were included in the database with incremental total direct cost of US$86,413,971 and indirect cost of US$138,492,987. This resulted in an average incremental direct cost of US$2050 per RA patient. Within direct costs, the largest burdens were associated with drugs (US$73,028,944), laboratory tests (US$6,132,395), and hospitalizations (US$3,208,559). For indirect costs, absenteeism costs and presenteeism costs were US$16,059,681 and US$114,291,687, respectively.

CONCLUSIONS: The economic burden of RA in Taiwan is driven by indirect healthcare costs, most notably presenteeism.

Original languageEnglish
Pages (from-to)107-114
Number of pages8
JournalDrugs - Real World Outcomes
Volume3
Issue number1
DOIs
Publication statusPublished - Mar 2016

Fingerprint

National Health Programs
Taiwan
Rheumatoid Arthritis
Economics
Databases
Costs and Cost Analysis
Absenteeism
Health Care Costs
Hospitalization
Research
Pharmaceutical Preparations
Autoimmune Diseases
Chronic Disease
Joints

Keywords

  • Journal Article

Cite this

Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database. / Wang, Bruce C M; Hsu, Ping-Ning; Furnback, Wesley; Ney, John; Yang, Ya-Wen; Fang, Chi-Hui; Tang, Chao-Hsiun.

In: Drugs - Real World Outcomes, Vol. 3, No. 1, 03.2016, p. 107-114.

Research output: Contribution to journalArticle

Wang, Bruce C M ; Hsu, Ping-Ning ; Furnback, Wesley ; Ney, John ; Yang, Ya-Wen ; Fang, Chi-Hui ; Tang, Chao-Hsiun. / Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database. In: Drugs - Real World Outcomes. 2016 ; Vol. 3, No. 1. pp. 107-114.
@article{c1d99470a00b44588555ea86db1a35d4,
title = "Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database",
abstract = "BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of the joints.OBJECTIVES: This research aims to estimate the economic burden of RA in Taiwan.METHODS: The National Health Insurance Research Database (NHIRD), a claims-based dataset encompassing 99 {\%} of Taiwan's population, was applied. We used a micro-costing approach for direct healthcare costs and indirect social costs by estimating the quantities and prices of cost categories. Direct costs included surgeries, hospitalizations, medical devices and materials, laboratory tests, and drugs. The costs and quantities of the direct economic burden were calculated based on 2011 data of NHIRD. We identified RA patients and a control cohort matched 1:4 on demographic and clinical covariates to calculate the incremental cost related to RA. Indirect costs were evaluated by missed work (absenteeism) and worker productivity (presenteeism). For the indirect burden, we estimated the rate of absenteeism and presenteeism from a patient survey. Costs were presented in US dollars (US$1 = 30 TWD).RESULTS: A total of 41,269 RA patients were included in the database with incremental total direct cost of US$86,413,971 and indirect cost of US$138,492,987. This resulted in an average incremental direct cost of US$2050 per RA patient. Within direct costs, the largest burdens were associated with drugs (US$73,028,944), laboratory tests (US$6,132,395), and hospitalizations (US$3,208,559). For indirect costs, absenteeism costs and presenteeism costs were US$16,059,681 and US$114,291,687, respectively.CONCLUSIONS: The economic burden of RA in Taiwan is driven by indirect healthcare costs, most notably presenteeism.",
keywords = "Journal Article",
author = "Wang, {Bruce C M} and Ping-Ning Hsu and Wesley Furnback and John Ney and Ya-Wen Yang and Chi-Hui Fang and Chao-Hsiun Tang",
year = "2016",
month = "3",
doi = "10.1007/s40801-016-0063-8",
language = "English",
volume = "3",
pages = "107--114",
journal = "Drugs - Real World Outcomes",
issn = "2198-9788",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database

AU - Wang, Bruce C M

AU - Hsu, Ping-Ning

AU - Furnback, Wesley

AU - Ney, John

AU - Yang, Ya-Wen

AU - Fang, Chi-Hui

AU - Tang, Chao-Hsiun

PY - 2016/3

Y1 - 2016/3

N2 - BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of the joints.OBJECTIVES: This research aims to estimate the economic burden of RA in Taiwan.METHODS: The National Health Insurance Research Database (NHIRD), a claims-based dataset encompassing 99 % of Taiwan's population, was applied. We used a micro-costing approach for direct healthcare costs and indirect social costs by estimating the quantities and prices of cost categories. Direct costs included surgeries, hospitalizations, medical devices and materials, laboratory tests, and drugs. The costs and quantities of the direct economic burden were calculated based on 2011 data of NHIRD. We identified RA patients and a control cohort matched 1:4 on demographic and clinical covariates to calculate the incremental cost related to RA. Indirect costs were evaluated by missed work (absenteeism) and worker productivity (presenteeism). For the indirect burden, we estimated the rate of absenteeism and presenteeism from a patient survey. Costs were presented in US dollars (US$1 = 30 TWD).RESULTS: A total of 41,269 RA patients were included in the database with incremental total direct cost of US$86,413,971 and indirect cost of US$138,492,987. This resulted in an average incremental direct cost of US$2050 per RA patient. Within direct costs, the largest burdens were associated with drugs (US$73,028,944), laboratory tests (US$6,132,395), and hospitalizations (US$3,208,559). For indirect costs, absenteeism costs and presenteeism costs were US$16,059,681 and US$114,291,687, respectively.CONCLUSIONS: The economic burden of RA in Taiwan is driven by indirect healthcare costs, most notably presenteeism.

AB - BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of the joints.OBJECTIVES: This research aims to estimate the economic burden of RA in Taiwan.METHODS: The National Health Insurance Research Database (NHIRD), a claims-based dataset encompassing 99 % of Taiwan's population, was applied. We used a micro-costing approach for direct healthcare costs and indirect social costs by estimating the quantities and prices of cost categories. Direct costs included surgeries, hospitalizations, medical devices and materials, laboratory tests, and drugs. The costs and quantities of the direct economic burden were calculated based on 2011 data of NHIRD. We identified RA patients and a control cohort matched 1:4 on demographic and clinical covariates to calculate the incremental cost related to RA. Indirect costs were evaluated by missed work (absenteeism) and worker productivity (presenteeism). For the indirect burden, we estimated the rate of absenteeism and presenteeism from a patient survey. Costs were presented in US dollars (US$1 = 30 TWD).RESULTS: A total of 41,269 RA patients were included in the database with incremental total direct cost of US$86,413,971 and indirect cost of US$138,492,987. This resulted in an average incremental direct cost of US$2050 per RA patient. Within direct costs, the largest burdens were associated with drugs (US$73,028,944), laboratory tests (US$6,132,395), and hospitalizations (US$3,208,559). For indirect costs, absenteeism costs and presenteeism costs were US$16,059,681 and US$114,291,687, respectively.CONCLUSIONS: The economic burden of RA in Taiwan is driven by indirect healthcare costs, most notably presenteeism.

KW - Journal Article

U2 - 10.1007/s40801-016-0063-8

DO - 10.1007/s40801-016-0063-8

M3 - Article

VL - 3

SP - 107

EP - 114

JO - Drugs - Real World Outcomes

JF - Drugs - Real World Outcomes

SN - 2198-9788

IS - 1

ER -